U.S. FDA warns of ADHD drug Adderall scarcity on Teva manufacturing delays By Reuters
Business

U.S. FDA warns of ADHD drug Adderall scarcity on Teva manufacturing delays By Reuters

admin



© Reuters. FILE PHOTO: A employee sweeps exterior of the Meals and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

(Reuters) -The U.S. Meals and Drug Administration mentioned on Wednesday there was a scarcity of Adderall, a therapy for consideration deficit hyperactivity dysfunction, following intermittent manufacturing delays at Teva Pharmaceutical Industries (NYSE:) Ltd.

Adderall is an FDA-approved prescription drug made from two stimulants amphetamine and dextroamphetamine.

Different producers proceed to supply amphetamine blended salts, however there may be not adequate provide to proceed to fulfill U.S. market demand by way of these producers, the U.S. well being regulator mentioned.

U.S.-listed shares of Israel-based Teva have been down 2% at $7.90 in buying and selling after the bell.

Teva didn’t instantly reply to a request for remark.